These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9829750)

  • 1. Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts.
    Pratesi G; De Cesare M; Caserini C; Perego P; Dal Bo L; Polizzi D; Supino R; Bigioni M; Manzini S; Iafrate E; Salvatore C; Casazza A; Arcamone F; Zunino F
    Clin Cancer Res; 1998 Nov; 4(11):2833-9. PubMed ID: 9829750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
    Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
    Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
    Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
    Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
    De Cesare M; Pratesi G; Perego P; Carenini N; Tinelli S; Merlini L; Penco S; Pisano C; Bucci F; Vesci L; Pace S; Capocasa F; Carminati P; Zunino F
    Cancer Res; 2001 Oct; 61(19):7189-95. PubMed ID: 11585754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
    Chen CT; Gan Y; Au JL; Wientjes MG
    Cancer Res; 1998 Jul; 58(13):2777-83. PubMed ID: 9661891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
    Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse.
    Giuliani FC; Kaplan NO
    Cancer Res; 1980 Dec; 40(12):4682-7. PubMed ID: 7438099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
    Frankel A; Man S; Elliott P; Adams J; Kerbel RS
    Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.
    Plonowski A; Schally AV; Nagy A; Sun B; Szepeshazi K
    Cancer Res; 1999 Apr; 59(8):1947-53. PubMed ID: 10213505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM; Schally AV; Halmos G; Nagy A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
    Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.
    Boven E; Winograd B; Berger DP; Dumont MP; Braakhuis BJ; Fodstad O; Langdon S; Fiebig HH
    Cancer Res; 1992 Nov; 52(21):5940-7. PubMed ID: 1394220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel bifunctional anthracycline and nitrosourea chemotherapy for human bladder cancer: analysis in a preclinical survival model.
    Glaves D; Murray MK; Raghavan D
    Clin Cancer Res; 1996 Aug; 2(8):1315-9. PubMed ID: 9816302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical antitumor activity of bizelesin in mice.
    Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J
    Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.
    Hjarnaa PJ; Jonsson E; Latini S; Dhar S; Larsson R; Bramm E; Skov T; Binderup L
    Cancer Res; 1999 Nov; 59(22):5751-7. PubMed ID: 10582695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
    Cao S; McGuire JJ; Rustum YM
    Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.